Characterization of a reliable cell-based reporter gene assay for measuring bioactivities of therapeutic anti-interleukin-23 monoclonal antibodies

Oppmann, 2000, Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12, Immunity, 13, 715, 10.1016/S1074-7613(00)00070-4

Wilson, 2007, Development, cytokine profile and function of human interleukin 17-producing helper T cells, Nat. Immunol., 8, 950, 10.1038/ni1497

Duvallet, 2011, Interleukin-23: a key cytokine in inflammatory diseases, Ann. Med., 43, 503, 10.3109/07853890.2011.577093

Lankford, 2003, A unique role for IL-23 in promoting cellular immunity, J. Leukoc. Biol., 73, 49, 10.1189/jlb.0602326

Park, 2005, A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17, Nat. Immunol., 6, 1133, 10.1038/ni1261

Parham, 2002, A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R, J. Immunol., 168, 5699, 10.4049/jimmunol.168.11.5699

Lee, 2004, Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris, J. Exp. Med., 199, 125, 10.1084/jem.20030451

Ahern, 2010, Interleukin-23 drives intestinal inflammation through direct activity on T cells, Immunity, 33, 279, 10.1016/j.immuni.2010.08.010

Raza, 2005, Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin, Arthritis Res. Ther., 7, R784, 10.1186/ar1733

Koh, 2019, IL-23-producing human lung cancer cells promote tumor growth via conversion of innate lymphoid cell 1 (ILC1) into ILC3, Clin. Cancer Res., 10.1158/1078-0432.CCR-18-3458

Wiekowski, 2001, Ubiquitous transgenic expression of the IL-23 subunit p19 induces multiorgan inflammation, runting, infertility, and premature death, J. Immunol., 166, 7563, 10.4049/jimmunol.166.12.7563

Yago, 2007, IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats, Arthritis Res. Ther., 9, R96, 10.1186/ar2297

Gottlieb, 2009, Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial, Lancet, 373, 633, 10.1016/S0140-6736(09)60140-9

Sofen, 2014, Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis, J. Allergy Clin. Immunol., 133, 1032, 10.1016/j.jaci.2014.01.025

Papp, 2015, Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial, Br. J. Dermatol., 173, 930, 10.1111/bjd.13932

Reich, 2019, Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial, Lancet, 394, 576, 10.1016/S0140-6736(19)30952-3

Sasaki-Iwaoka, 2018, Generation and characterization of a potent fully human monoclonal antibody against the interleukin-23 receptor, Eur. J. Pharmacol., 828, 89, 10.1016/j.ejphar.2018.03.036

International Conference on Harmonization (ICH) Guidelines ICH Q6B, Specifications: Test procedures and acceptance criteria for biotechnological/biological products. ICH: Geneva, Switzerland, 1999. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q6B/Step4/Q6B_Guideline.pdf.

Aggarwal, 2003, Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17, J. Biol. Chem., 278, 1910, 10.1074/jbc.M207577200

Meager, 2006, Measurement of cytokines by bioassays: theory and application, Methods, 38, 237, 10.1016/j.ymeth.2005.11.005

Wang, 2019, Development of reporter gene assays to determine the bioactivity of biopharmaceuticals, Biotechnol. Adv., 107466

Lee, 2019, Characterization of a single reporter-gene potency assay for T-cell-dependent bispecific molecules, MAbs., 11, 1245, 10.1080/19420862.2019.1640548

Yu, 2018, Measuring the bioactivity of anti-IL-6/anti-IL-6R therapeutic antibodies: presentation of a robust reporter gene assay, Anal. Bioanal. Chem., 410, 7067, 10.1007/s00216-018-1307-0

Hawe, 2012, Forced degradation of therapeutic proteins, J. Pharm. Sci., 101, 895, 10.1002/jps.22812

ICH, International Conference on Harmonization (ICH) Guidelines ICH Q2(R1), Validation of Analytical Procedures:Text and Methodology; ICH: Geneva, Switzerland, 2005. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf.

Chinese Pharmacopoeia Commission.Chinese Pharmacopoeia, 4th ed.; People’s Medical Publishing House:Beijing, China, 2015.

Capon, 2007, Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis, Hum. Genet., 122, 201, 10.1007/s00439-007-0397-0

Yago, 2017, IL-23 and Th17 Disease in Inflammatory Arthritis, J Clin Med., 6, 81, 10.3390/jcm6090081

Liu, 2011, The increased expression of IL-23 in inflammatory bowel disease promotes intraepithelial and lamina propria lymphocyte inflammatory responses and cytotoxicity, J. Leukoc. Biol., 89, 597, 10.1189/jlb.0810456

Kamada, 2008, Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis, J Clin Invest., 118, 2269

Murphy, 2003, Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation, J. Exp. Med., 198, 1951, 10.1084/jem.20030896

Ghandi, 2019, Next-generation characterization of the Cancer Cell Line Encyclopedia, Nature, 569, 503, 10.1038/s41586-019-1186-3

Rozovski, 2017, Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex, Mol. Cancer Res., 15, 610, 10.1158/1541-7786.MCR-16-0291

Park, 1998, c-Fes tyrosine kinase binds to and activates STAT3 after granulocyte-macrophage colony-stimulating factor stimulation, Cancer Lett., 129, 29, 10.1016/S0304-3835(98)00077-9